{"id":19574,"date":"2025-06-12T11:02:54","date_gmt":"2025-06-12T11:02:54","guid":{"rendered":"https:\/\/planescomplementariossalud.es\/?p=19574"},"modified":"2025-06-12T11:07:41","modified_gmt":"2025-06-12T11:07:41","slug":"livetox","status":"publish","type":"post","link":"https:\/\/planescomplementariossalud.es\/eu\/livetox\/","title":{"rendered":"LIVETOX"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:300px\">\n<figure class=\"wp-block-image alignright size-full is-resized has-custom-border\"><img fetchpriority=\"high\" decoding=\"async\" width=\"469\" height=\"512\" src=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2025\/06\/Imatge1-1.png\" alt=\"\" class=\"wp-image-19578\" style=\"border-radius:7px;width:429px;height:auto\" srcset=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2025\/06\/Imatge1-1.png 469w, https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2025\/06\/Imatge1-1-275x300.png 275w\" sizes=\"(max-width: 469px) 100vw, 469px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-ast-global-color-6-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:10px;padding-right:10px;padding-bottom:10px;padding-left:10px\">\n<h2 class=\"wp-block-heading\">Profiling de nanopart\u00edculas y toxicidad <em>in vivo<\/em><\/h2>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:2px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-ast-global-color-6-background-color has-background\"><strong>LINEA DE ACTUACI\u00d3N 5:<\/strong> DESARROLLO DE NANOF\u00c1RMACOS, BIODISTRIBUCI\u00d3N, TOXICIDAD Y ACCIONES TERAP\u00c9UTICAS EN MODELOS DE PATOLOG\u00cdA<br>Linea de actuaci\u00f3n complementaria: LA3. Plataforma de cribado de f\u00e1rmacos y an\u00e1lisis interacciones f\u00e1rmaco-diana<br><br><strong>Palabras clave:<\/strong> Glioblastoma, siRNA, nanopart\u00edculas, nanomedicina<br><strong>Coordina:<\/strong> Universidad de Castilla-La Mancha<br><strong>Participa:<\/strong> Servicio de Salud de Castilla-La Mancha SESCAM (Castilla-La Mancha); Fundaci\u00f3n Kaertor (Galicia)<br><strong>Persona de contacto:<\/strong> Valent\u00edn Ce\u00f1a (valentin.cena@gmail.com)<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column has-ast-global-color-4-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:20px;padding-right:20px;padding-bottom:20px;padding-left:20px\">\n<p>El proyecto LIVETOX representa un paso adelante en el desarrollo de nanopart\u00edculas terap\u00e9uticas, ya que pretende, por una parte, realizar un estudio del \u201cprofiling\u201d de 3 compuestos cabeza de serie pertenecientes a 3 familias qu\u00edmicas diferentes y, por otra, realizar estudios bioqu\u00edmicos sobre la toxicidad plasm\u00e1tica&nbsp; de la administraci\u00f3n aguda&nbsp; de los compuestos sobre los marcadores bioqu\u00edmicos en el plasma de rat\u00f3n. En cuanto al estudio del \u201cprofiling\u201d de dichas nanopart\u00edculas se estudiar\u00e1n en este&nbsp; proyecto, entre otros par\u00e1metros, el efecto de las nanopart\u00edculas sobre una bater\u00eda de canales i\u00f3nicos (incluyendo los canales HERG) y sobre un panel de quinasas&nbsp; implicadas en diversas v\u00edas de se\u00f1alizaci\u00f3n intracelular con el objeto de identificar mecanismos de acci\u00f3n no esperados que puedan convertirse tanto en una nueva acci\u00f3n farmacol\u00f3gica como&nbsp; descartar o predecir una posible toxicidad de las nanopart\u00edculas.<\/p>\n\n\n\n<p>Por otra parte, se buscar\u00e1 toxicidad directa de las nanopart\u00edculas sobre par\u00e1metros plasm\u00e1ticos en ratones utilizando un rango de dosis creciente que supere ampliamente la dosis a utilizar para vehiculizar siRNA. En esta parte del proyecto se determinar\u00e1 el efecto de las nanopart\u00edculas sobre par\u00e1metros como glucosa, perfil lip\u00eddico, perfil hep\u00e1tico y perfil renal. Toda esta informaci\u00f3n permitir\u00e1 determinar predecir la posibilidad de que las nanopart\u00edculas que han mostrado efectividad para transfectar siRNA en otros proyectos puedan ser t\u00f3xicas cuando se utilizan en animales como prueba previa a su posible utilizaci\u00f3n en humanos.<\/p>\n\n\n\n<p>En conjunto, el proyecto LIVETOX permitir\u00e1 avanzar en el camino hacia una posible utilizaci\u00f3n terap\u00e9utica de estas nanopart\u00edculas, bien solas o complejadas con siRNA.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"ast-oembed-container \" style=\"height: 100%;\"><iframe title=\"Proyecto LIVETOX - Profiling de nanopart\u00edculas y toxicidad in vivo\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/b7WYOYF0Tzc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-ast-global-color-6-color has-alpha-channel-opacity has-ast-global-color-6-background-color has-background\"\/>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\">COORDINA:<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\">PARTICIPA: <\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\"><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img decoding=\"async\" width=\"1514\" height=\"381\" src=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2024\/03\/Logo_uclm.png\" alt=\"\" class=\"wp-image-9499\" style=\"width:233px;height:auto\" srcset=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2024\/03\/Logo_uclm.png 1514w, https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2024\/03\/Logo_uclm-300x75.png 300w, https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2024\/03\/Logo_uclm-1024x258.png 1024w, https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2024\/03\/Logo_uclm-768x193.png 768w\" sizes=\"(max-width: 1514px) 100vw, 1514px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img decoding=\"async\" width=\"336\" height=\"305\" src=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2022\/06\/sescam.jpg\" alt=\"\" class=\"wp-image-687\" style=\"width:141px;height:auto\" srcset=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2022\/06\/sescam.jpg 336w, https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2022\/06\/sescam-300x272.jpg 300w\" sizes=\"(max-width: 336px) 100vw, 336px\" \/><\/figure>\n\n\n\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"186\" height=\"71\" src=\"https:\/\/planescomplementariossalud.es\/wp-content\/uploads\/2022\/06\/kaertor.png\" alt=\"\" class=\"wp-image-673\" style=\"width:204px;height:auto\"\/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-ast-global-color-6-color has-alpha-channel-opacity has-ast-global-color-6-background-color has-background\"\/>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p><i>L\u00ednea de actuaci\u00f3n 5 (LA5)<\/i><\/p>\n<p><&#038;nbsp><br \/>\n<\/p>\n<p>Nanopart\u00edculas para administrar ARNip a xenoinjertos de glioblastoma derivados de pacientes<\/p>\n<p><&#038;nbsp><br \/>\n<strong>Palabras clave:<\/strong> Glioblastoma, nanopart\u00edculas, toxicidad, in vivo.<\/p>\n","protected":false},"author":15,"featured_media":19579,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[244],"tags":[185,204,132],"class_list":["post-19574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-proyecto-eu","tag-castilla-la-mancha-eu","tag-nanofarmacos-eu","tag-proyecto-colaborativo-eu"],"_links":{"self":[{"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/posts\/19574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/comments?post=19574"}],"version-history":[{"count":2,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/posts\/19574\/revisions"}],"predecessor-version":[{"id":19590,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/posts\/19574\/revisions\/19590"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/media\/19579"}],"wp:attachment":[{"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/media?parent=19574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/categories?post=19574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/planescomplementariossalud.es\/eu\/wp-json\/wp\/v2\/tags?post=19574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}